Affymax (OTC:AFFY) prints at $3.41 premarket, -78.8%, following yesterday's report of the Omontys recall. AFFY has no other late-stage drugs in its pipeline. Piper expects shares to trade to cash value (~$2) "as investors take into account the lack of visibility." In play: AMGN, whose Epogen dominates the antianemia market (+2.4%), NKTR (which earns royalties on Omontys sales), and FMS, which pulled a trial two weeks ago (-1.3%).
Affymax (OTC:AFFY) prints at $3.41 premarket, -78.8%, following yesterday's report of the...
Recommended For You
More Trending News
About AFFY Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
AFFY | - | - |
Affymax, Inc. |